Rapid Micro Biosystems Q4 revenue $6.3M (+45% YoY); guides FY2024 revenue ≥$27M

RAPID MICRO BIOSYSTEMS, INC.

Q4 2023 revenue $6.3M (+45% YoY); placed 6 Growth Direct systems, highest since Q3 2021.
FY2023 revenue $22.5M (+31% YoY); net loss $52.5M vs $60.8M in 2022, loss narrowed.
Gross margin improved to near breakeven (-3%) from -59% in Q4 2022 on cost actions.
Cash $95M, no debt; expected runway into H2 2026.
FY2024 guidance: revenue ≥$27M, at least 20 system placements; new Rapid Sterility app by mid-2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

RAPID MICRO BIOSYSTEMS, INC. updated its fourth quarter and fiscal year ended December 31, 2023 guidance (initiated).

Period: fourth quarter and fiscal year ended December 31, 2023
Guidance: initiated
Result: reported results

Exact text from the filing

On March 1, 2024, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fourth quarter and fiscal year ended December 31, 2023.

View on SEC.gov

41 earnings releases filed in the last 30 days. Browse all earnings releases →

RAPID MICRO BIOSYSTEMS, INC. filing history →

Source: SEC EDGAR

accession 0001380106-24-000058

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.